Who is sponsoring NCT03428412?

NCT03428412 is sponsored by Henan University of Traditional Chinese Medicine.

What drugs are being tested in NCT03428412?

Interventions in NCT03428412: TCM and conventional drug, TCM placebo and conventional drug.

What condition does NCT03428412 study?

NCT03428412 studies Pulmonary Disease, Chronic Obstructive, Acute Exacerbation, Medicine, Chinese Traditional.

Is NCT03428412 still recruiting?

NCT03428412 is currently status unknown. Last updated 9 February 2018.

Last reviewed 2018-02-09 · How we verify

NCT03428412

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Traditional Chinese Medicine on AECOPD Patients

Status unknown Phase 3 Last updated 9 February 2018

What this trial tests

Phase 3 trial testing TCM and conventional drug in Pulmonary Disease, Chronic Obstructive in 378 participants. Status unknown.

Timeline

1 March 2018

Primary endpoint
30 September 2019

31 December 2019

Quick facts

Lead sponsor	Henan University of Traditional Chinese Medicine
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	378
Start date	1 March 2018
Primary completion	30 September 2019
Estimated completion	31 December 2019

Drugs / interventions tested

TCM and conventional drug — full drug profile →
TCM placebo and conventional drug

Conditions studied

Pulmonary Disease, Chronic Obstructive — all drugs for Pulmonary Disease, Chronic Obstructive →
Acute Exacerbation — all drugs for Acute Exacerbation →
Medicine, Chinese Traditional — all drugs for Medicine, Chinese Traditional →

Sponsor

Henan University of Traditional Chinese Medicine

Who can join

Adults 40 to 80, any sex, with Pulmonary Disease, Chronic Obstructive or Acute Exacerbation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, randomized, double-blind, controlled trial to compare the efficacy of two therapies for patients with AECOPD. 378 subjects will be randomly assigned to one therapies (conventional drug, and the combination of conventional drug and TCM) for 14 days treatment. After the treatment period, subjects in two arms will be followed up for 4 weeks. The primary outcomes will include COPD Assessment Test (CAT), and secondary outcomes include treatment failure rate, treatment success rate, hospitalization time, hospital admission rate, endotracheal intubation rate, mortality and quality of life (COPD-PRO, SF-36).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Effects of Chinese Herbal Medicine on Acute Exacerbations of COPD: A Randomized, Placebo-Controlled Study.
Li J, Zhang H, Ruan H, Si Y, et al · · 2020 · cited 22× · PMID 33209019 · DOI 10.2147/copd.s276082
Effects of Chinese medicine on patients with acute exacerbations of COPD: study protocol for a randomized controlled trial.
Zhang H, Li J, Yu X, Li S, et al · · 2019 · cited 5× · PMID 31842969 · DOI 10.1186/s13063-019-3772-y

Verify or expand the search:

Other recruiting trials for Pulmonary Disease, Chronic Obstructive

Currently open trials in the same condition.

NCT07177339 — eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (CO · Phase 3 · recruiting
NCT06961214 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06959095 — Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and T · Phase 3 · recruiting
NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
NCT06712563 — Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting · recruiting

Other Henan University of Traditional Chinese Medicine trials

Trials by the same sponsor.

NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03428412 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
Last refreshed: 9 February 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03428412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing